TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT02678806

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Description: The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative TACE
Description: In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 \~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
Study: NCT04536194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine
Description: to treat hypotension under general anesthesia with norepinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dopamine
Description: to treat hypotension under general anesthesia with dopamine
Study: NCT03289689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Description: Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
Study: NCT01956981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Sulfate
Description: 40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
Study: NCT00482846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is \>40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;
Study: NCT00096291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel followed by Doxorubicin
Description: Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin

Intervention type: OTHER
Group type: OTHER
Intervention: Paclitaxel followed by Doxorubicin
Description: Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin
Study: NCT03098394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cepheid Xpert CT/NG Rapid Turnaround Test
Description: This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Description: This is the standard of care for diagnosis of a suspected sexually transmitted infection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymerase chain reaction (PCR)
Description: This is the standard of care for diagnosis of a suspected sexually transmitted infection.
Study: NCT00990769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depth of anesthesia
Description: The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depth of anesthesia
Description: The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
Study: NCT01214720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Intervenous repeating dose
Study: NCT03313323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 89Zirconium-labeled ipilimumab
Description: Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
Study: NCT02775812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01319383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
Study: NCT02284490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
Study: NCT01452815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg TZP-102
Description: One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg TZP-102
Description: Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
Study: NCT00745420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~* Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~* Fludarabine: 30 mg/m\^2/day IV on Days -8 through -4~* Melphalan: 140 mg/m\^2 IV on Day -3~* Rest on Days -2 and -1~* Transplant occurs on Day 0~* GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD
Study: NCT02486900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback
Description: During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
Study: NCT03214952

Intervention type: DRUG
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study: NCT05074576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan group
Description: Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
Study: NCT01149590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer Tomography Angiography
Description: Computed Tomography Angiography
Study: NCT01111045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bone morphogenetic protein 7
Description: Comparison of different doses of the drug via single intraarticular knee injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bone morphogenetic protein 7
Description: Comparison of different doses of the drug via single intraarticular knee injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bone morphogenetic protein 7
Description: Comparison of different doses of the drug via single intraarticular knee injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02679703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High voltage
Description: Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
Study: NCT04302025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Participants will receive oral entrectinib daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib (Enrollment closed)
Description: Participants will receive oral vemurafenib BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib (Enrollment closed)
Description: Participants will receive oral cobimetinib daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib (Enrollment closed)
Description: Participants will receive oral pralsetinib daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will receive SBRT given concurrently starting with the first dose of atezolizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Participants will receive surgical resection of the primary tumor along with selected lymph nodes
Study: NCT00482846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Day -5 to Day +28

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous peripheral blood stem cell transplantation
Description: Day 0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Day -5 to Day +28
Study: NCT01491945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventana Fenestrated Stent Graft System
Description: The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts
Study: NCT00929032

Intervention type: RADIATION
Intervention: Nanocoll®
Description: To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
Study: NCT03236389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q Collar
Description: measuring changes in brain during MRI while wearing the Q collar
Study: NCT04302025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Participants will receive surgical resection of the primary tumor along with selected lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Participants will receive surgical resection of the primary tumor along with selected lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Participants will receive surgical resection of the primary tumor along with selected lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Participants will receive surgical resection of the primary tumor along with selected lymph nodes
Study: NCT03502122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR rehabilitation for motor function
Description: rehabilitation for motor function

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR rehabilitation for motor function
Description: rehabilitation for motor function
Study: NCT00306488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-551 antioxidant eye drop
Description: 0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
Study: NCT02205021

Intervention type: OTHER
Intervention: No intervention
Study: NCT00062504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: 10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: 10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: 10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
Study: NCT02208622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study 1: Whey Supplement Day 1
Description: Whey supplement was given on day 1, control diet on day 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study 1: Whey Supplement Day 2
Description: Control diet was given day 1, whey supplement was given day 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study 2: Whey Supplement
Description: Whey supplement was given as part of diet for both day 1 and 2 of study
Study: NCT01813643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
Study: NCT01026038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
Study: NCT03972228

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice loaded with 19 chemotherapeutic agents
Description: The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
Study: NCT00554723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeuroAid
Description: 4 capsules 3 times daily, for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NeuroAid matched Placebo
Description: NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
Study: NCT01346683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed TX
Description: OsseoSpeed TX implants of lengths 8-17 mm
Study: NCT03543267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI exam
Description: MRI before and after resection surgery
Study: NCT03601052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remlarsen
Description: Intradermal injection at site of one excisional wound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection at site of second excisional wound
Study: NCT04481282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: 2.5mg po tid for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: 200mg po bid for 12 weeks
Study: NCT01402466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Referral
Description: Participants randomized to this arm will be referred to local HIV care resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Bridge
Description: Arm 2
Study: NCT02509702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connected to Care
Description: 10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
Study: NCT01227395

Intervention type: DRUG
Intervention: Azithromycin
Description: Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.
Study: NCT01940146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPARC Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1310 I
Description: SPARC1310 I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1310 II
Description: SPARC1310 II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1310 III
Description: SPARC1310 III
Study: NCT01789775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: CD07805/47 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 gel Placebo
Study: NCT01550185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag olamine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Description: Receive standard care
Study: NCT01003626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Interstitial Fluid Pressure (IFP) assessments
Description: The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transducer-catheter SPC-320 + Amplifier
Description: Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
Study: NCT03537677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction in Sedentary Behavior
Description: This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
Study: NCT00222274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RSA Biofeedback
Description: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J\&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EEG Biofeedback Condition
Description: EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J\&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
Study: NCT02958670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451 (Tau-PET tracer)
Description: Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan